HUMA vs. TARS, JANX, AGIO, NAMS, IDYA, SDGR, TVTX, BLTE, VERA, and IOVA
Should you be buying Humacyte stock or one of its competitors? The main competitors of Humacyte include Tarsus Pharmaceuticals (TARS), Janux Therapeutics (JANX), Agios Pharmaceuticals (AGIO), NewAmsterdam Pharma (NAMS), IDEAYA Biosciences (IDYA), Schrödinger (SDGR), Travere Therapeutics (TVTX), Belite Bio (BLTE), Vera Therapeutics (VERA), and Iovance Biotherapeutics (IOVA). These companies are all part of the "pharmaceutical products" industry.
Humacyte vs.
Tarsus Pharmaceuticals (NASDAQ:TARS) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, risk, earnings, dividends and media sentiment.
Humacyte has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -103.64%. Tarsus Pharmaceuticals' return on equity of -55.86% beat Humacyte's return on equity.
Tarsus Pharmaceuticals presently has a consensus price target of $56.00, indicating a potential upside of 17.06%. Humacyte has a consensus price target of $13.71, indicating a potential upside of 286.86%. Given Humacyte's higher probable upside, analysts plainly believe Humacyte is more favorable than Tarsus Pharmaceuticals.
90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 8.3% of Tarsus Pharmaceuticals shares are owned by company insiders. Comparatively, 11.2% of Humacyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Humacyte has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.
Tarsus Pharmaceuticals received 13 more outperform votes than Humacyte when rated by MarketBeat users. However, 67.31% of users gave Humacyte an outperform vote while only 66.67% of users gave Tarsus Pharmaceuticals an outperform vote.
Tarsus Pharmaceuticals has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500.
In the previous week, Tarsus Pharmaceuticals had 2 more articles in the media than Humacyte. MarketBeat recorded 4 mentions for Tarsus Pharmaceuticals and 2 mentions for Humacyte. Humacyte's average media sentiment score of 0.98 beat Tarsus Pharmaceuticals' score of 0.87 indicating that Humacyte is being referred to more favorably in the news media.
Summary
Humacyte beats Tarsus Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get Humacyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Humacyte Competitors List
Related Companies and Tools
This page (NASDAQ:HUMA) was last updated on 2/22/2025 by MarketBeat.com Staff
